• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ: ALXO )

1.620 +0.140 (+9.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,165,199
Open 1.510
Bid (Size) 1.590 (6)
Ask (Size) 1.610 (1)
Prev. Close 1.480
Today's Range 1.510 - 1.670
52wk Range 1.190 - 17.82
Shares Outstanding 40,869,135
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
December 18, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
December 12, 2024
From ALX Oncology
Via GlobeNewswire

Performance

YTD
-88.87%
-88.87%
1 Month
+25.58%
+25.58%
3 Month
-18.59%
-18.59%
6 Month
-75.27%
-75.27%
1 Year
-89.47%
-89.47%

More News

Read More
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
December 10, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
November 14, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 07, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces November Investor Conference Participation
November 04, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
November 01, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
September 09, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
September 04, 2024
From ALX Oncology
Via GlobeNewswire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
August 27, 2024
Via Benzinga
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024
August 09, 2024
Via InvestorPlace
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
August 06, 2024
From ALX Oncology
Via GlobeNewswire
Crude Oil Moves Lower; Moderna Shares Plunge
August 01, 2024
Via Benzinga
Exposures Fossil Fuels
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
August 01, 2024
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
August 01, 2024
Via Benzinga
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
August 01, 2024
Via Benzinga
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
August 01, 2024
Via Benzinga
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
July 31, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
July 31, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 02, 2024
From ALX Oncology
Via GlobeNewswire
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
May 29, 2024
From ALX Oncology
Via GlobeNewswire
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024
May 09, 2024
Via InvestorPlace
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From ALX Oncology
Via GlobeNewswire
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap